Clinical trials: Healthy Volunteers.
Healthy
Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets…
- Trial name
- NCT00835042
- Testing
- Moexipril HCl/hydrochlorothiazide 15/25 mg tablets, UNIRETIC® 15/25 mg tablets
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
A Study to Evaluate Single-dose of HB0056 in Healthy Adult Participants
The aim of this study is to investigate the safety and tolerability of HB0056 in healthy subjects following single-dose.
- Trial name
- NCT06612970
- Testing
- HB0056
- Where
- New Zealand
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Healthy
A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
- Trial name
- NCT04045769
- Testing
- Saroglitazar magnesium 4mg, Moxifloxacin 400mg, Saroglitazar magnesium 20 mg
- Where
- India
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.
- Trial name
- NCT07647783
- Testing
- SYH2072 Tablets
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- InnovStone Therapeutics Limited
Influenza
Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
This study was designed in two steps with Step 1, a single-center, double-blind, randomized clinical Pilot study and Step 2, a multi-center, single-blind, randomized clinical Pivotal study.
- Trial name
- NCT01389466
- Testing
- Step 1, Step 2
- Where
- 4 sites in South Korea
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Healthy
Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
This study investigated the bioequivalence of the 100 milligrams (mg) and 250 mg dose strengths of tepotinib tablet formulation 3 (TF3) when administered at the same dose under fasted condition.
- Trial name
- NCT04204902
- Testing
- Tepotinib 100 mg, Tepotinib 250 mg
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Asthma, COPD
An Evaluation of 9MW1911 Injection in Healthy Subjects
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
- Conditions
- Asthma, COPD, Atopic Dermatitis
- Trial name
- NCT05803902
- Testing
- Experimental drug 9MW1911
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Healthy
A Study of LY3866288 in Healthy Participants
The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally.
- Trial name
- NCT06641037
- Testing
- LY3866288
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metabolic Dysfunction-Associated Steatohepatitis
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
This Phase 1 trial will explore the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses of INI-822 in healthy volunteers in Parts A, B, D and F and in participants with a…
- Trial name
- NCT05945537
- Testing
- INI-822 (A)
- Where
- 11 sites in Australia
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Inipharm Australia Pty Ltd
Healthy
A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects
This is an open-label study investigating the relationship between SEP-228432 and SEP-228431 (the active metabolite of SEP-228432) plasma concentrations, SERT occupancy, and DAT occupancy, both measured by SPECT imaging.
- Trial name
- NCT01531972
- Testing
- SEP-228432
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Type2 Diabetes Mellitus
A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Adult Volunteers
The purpose of this study is to evaluate the pharmacokinetics and Safety/Tolerability of CKD-386
- Trial name
- NCT04223895
- Testing
- CKD-386 Formulation 1, CKD-386 Formulation 2, D012, D326 and D337
- Volunteers
- 30 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
The primary objective of the study is to evaluate the effects of omeprazole (a proton-pump inhibitor) and an acidic beverage (Coca-Cola) on sotorasib pharmacokinetics (PK) when administered orally in healthy volunteers.
- Trial name
- NCT05497557
- Testing
- Omeprazole, Sotorasib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Amgen
Autoimmune Diseases
A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).
- Trial name
- NCT05418101
- Testing
- VIS171
- Where
- 10 sites in Bulgaria, Germany and 3 more
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy Subjects
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
This will be an investigator- and subject-blinded (sponsor open), randomized, placebo controlled, sequential, ascending, multiple oral dose study, with 5 planned cohorts (optional sixth and seventh cohorts).
- Trial name
- NCT03230383
- Testing
- PF-06865571
- Where
- 2 sites in United States, Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Elderly
MAD Study of NX210c
This study will investigate the safety and tolerability of multiple intravenous infusions of NX210c with two ascending doses as well as NX210c pharmacokinetics (PK), and pharmacodynamics (PD) effects in healthy elderly subjects.
- Trial name
- CHDR2235 (NCT05827653)
- Testing
- NX210c
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Axoltis Pharma
Healthy Volunteers
A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of single and multiple intravenous doses of SPR741 when administered to healthy adult volunteers.
- Trial name
- NCT03022175
- Testing
- SPR741
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Spero Therapeutics
Hepatic Impairment, Healthy Participants
An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
The purpose of this study is to investigate SHR6390 in participants with different levels of liver function
- Trial name
- NCT04631575
- Testing
- SHR6390
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy, Hepatic Insufficiency
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05916560
- Testing
- LY3437943
- Where
- 5 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.